Lv3
210 积分 2025-11-07 加入
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial
1小时前
已完结
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial
1个月前
已完结
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact
2个月前
已完结
Evolution and prognostic significance of HER-2 conversion from primary to residual disease in HER-2 negative patients with breast cancer after neoadjuvant chemotherapy
2个月前
已关闭
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2 positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis
2个月前
已完结
Targeting HER2 heterogeneity in breast and gastrointestinal cancers
2个月前
已完结
Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper
2个月前
已完结
皖公网安备34019202002308
